Background: This document updates the American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Idiopathic pulmonary fibrosis (IPF) is increasingly recog-nised as a well-known clinical and
highly complex entity associated with poor prognosis and a median survival of 3–5 yrs after …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …

The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be
approximately 3 years from the time of diagnosis, underscoring the lack of effective medical …

Idiopathic pulmonary fibrosis (IPF) is a devastating illness for which current therapy is
minimally effective. If medical therapy for IPF is going to improve over the next decade …

Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor
prognosis. Our objective is to assess the comparative effectiveness of 22 approved or …

Idiopathic pulmonary fibrosis (IPF) is a lethal form of idiopathic diffuse lung disorders for
which no current treatment is effective. The aim of the present study was to systematically …

Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …